Skip to main content

Table 2 Population estimates of the base and the final model for AS/DHA

From: Fixed dose artesunate amodiaquine – a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine

 

Base model

Final model

Parameter

Mean

Standard error

Mean

Standard error

KaAS(h−1)

2.45

0.34

2.41

0.34

CL/FAS (L/h)

797

102

616

98.4

V/FAS(L)

119

51.8

85.2

36.0

FM(%)

0.81

0.16

0.00781

0.00108

Kem (h−1)

0.819

0.266

0.742

0.166

ѲBWkem

NA

NA

1.65

0.46

ѲFORM

NA

NA

1.79

0.36

ω2CL/FAS

0.101

0.089

NE

NE

ω2V/FAS

1.94

2.23

2.21

2.27

ω2kemDHA

0.000352

0.0666

NE

NE

σ2adAS

0.000218

0.000122

0.000277

0.00015

σ2multAS

0.665

0.154

0.674

0.116

σ2adDHA

0.0438

0.0299

0.0324

0.0223

σ2multDHA

0.391

0.093

0.374

0.0726

  1. KaAS: absorption rate constant of AS, CL/FAS: apparent clearance of AS, V/FAS: apparent distribution volume of AS, FM: fraction of AS metabolized into DHA, K34 and K43: distribution rate constants of DAQ, Kem: elimination rate constant of DHA, ѲBWkm: influential factor of BW on DHA kem, ѲFORM : influence of dosage form on AS bioavailability, ω2CL/FAS: interindividual variability of CL/FAS, ω2V/FAS: interindividual variability of V/FAS, σ2multAS: proportional residual error for AS, σ2adAS: additive residual error for AS , σ2multDHA: proportional residual error for DHA, σ2adDHA: additive residual error for DHA, NA: Not Available, NE: Not Estimated.
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us